Pfizer raised profit estimates for 2025 thanks to cost cuts, despite falling COVID product revenue and patent expirations.
Sanziana Georgescu
Economy
sursa foto: shutterstock.com
Always see our news on Google
Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
23:12
Houthi militias in Yemen attacked two Saudi oil tankers, Wafa and Daisy, in the Red Sea and the Gulf of Aden
22:55
The British Foreign Secretary avoids answering whether he still considers Donald Trump an "idiot," "racist," and "misogynist."
22:41
Armed attack with multiple victims in Prospect Hill, North Carolina
22:20
An explosive drone was found on the runway of the airport in Leipzig / The German police deployed a bomb disposal robot
21:47
Iran and Oman have agreed on a shipping route through the Strait of Hormuz
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
